Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC

Kadimastem

In accordance with the MOU, Kadimastem will provide IMCC a loan of up to $650,000, which will be used by IMCC to restructure its current operations for sale allow Kadimastem to enter the public platform on the NASDAQ Kadimastem Ltd. (TASE: KDST), a leading cell therapy company in the clinical development stages of breakthrough products for the treatment of ALS and diabetes, has completed another step on the way to signing a merger with the U.S. NASDAQ listed company IMCC; IM Cannabis Corp (“IMCC”), (which is also listed in Canada on the CNSX) as reported several weeks ago, thus becoming a Nasdaq-listed company. The Company signed a loan agreement with IMCC, in accordance with their MOU. The loan amounts up to about $650,000 with the goal of organizing the current IMCC operations and preparing it for sale under a contingent value right (CVR) to be distributed to IMCC record shareholders prior to the consummation of the merger with Kadimastem', hence allowing Kadimastem to enter into IMCC’s public platform on the NASDAQ without taking ownership of IMCC’s current operations. Once and subject to the completion of the merger transaction and signing of the definitive documentation, pursuant to the MOU Kadimastem shareholders are expected to hold 88% of the shares of the combined company post -merger upon which Kadimastem will no longer be trading on the Tel Aviv Stock Exchange. The MOU is in line with the Company's strategic plan, to approach the target markets of its field of activity and the US capital markets. As part of the terms of the MOU, Kadimastem undertook to have approximately $5 million in funds, including capital raised simultaneously with the completion of the transaction and the commencement of trading from existing shareholders and additional investors. Ronen Twito, Executive Chairman of the Board said, "We are moving one step further towards a merger deal with IMCC that is planned to enable us to trade on the NASDAQ. This will assist Kadimastem’s development in the US capital markets especially in view of FDA approval to start a phase IIa multi-site clinical trial in the US for the ALS product candidate, as well as our development plans for additional product candidates, and especially the diabetes product candidate. I believe that together with IMCC’s professional management we will be able to promote the transaction quickly and professionally and generate significant value to our shareholders upon completion of the transaction." Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs. Kadimastem was founded in 2009 based on patent protected technology that was developed at Prof. Michel Revel’s laboratory at the Weizmann Institute of Science. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1613 s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

February 28, 2024 09:00 AM Eastern Standard Time

Image

Cyber Startup Secures 7 Million Networks, 500 Million Connected Devices – SAM Seamless Network Protects Customers Of Verizon, Virgin Media, Orange And Bezeq

OurCrowd

By Jeremy Ruden, Benzinga A small startup headed by a former officer in Israel’s elite 8200 Military Intelligence cyber unit is silently protecting 500 million connected devices in more than seven million homes and businesses around the world. This is the age of the Internet of Things (IoT) with millions of smart devices connected by Wi-Fi. From garage doors to smartwatches, all have access to private Wi-Fi, and many were designed without any attention to security. Once hacked, they provide a gateway into home and business networks where cyber criminals can wreak havoc, stealing personal information and holding entire companies to ransom. “In the US, an average household has 22 connected devices,” says Sivan Rauscher, a former 8200 officer and Co-Founder and CEO of SAM Seamless Network, an Israeli startup at the forefront of securing millions of IoT devices on a global level. “We record an average of 16 attacks a day on every network.” https://youtu.be/x94vQ0CBQyY?si=XHO89NQBkNcWzbpF Fueled by the spread of 5G wireless technology, the growth of smart devices snowballed during the pandemic – and the numbers keep growing. By the end of 2024, experts expect there will be more than 17 billion IoT devices connected worldwide. These are not just tablets or smartphones but include everything from household heating systems to online factory machinery. Many of the smart devices will also be enhanced with artificial intelligence, capable of making autonomous decisions. With this increased connectivity come major security concerns. “When you have more connected devices in your perimeter, you’re opening more back doors into your data,” says Rauscher, a rare female CEO in the male-dominated world of cyber security. “It’s just like when you move into a larger house, there are more entry points for thieves. It’s the same with information – the more connectivity, the larger the threat of a breach.” SAM is currently raising a funding round via OurCrowd, the Jerusalem-based investment platform that allows accredited investors to access privately held startups. Prime Target While major corporations can look to giants like Cisco (NASDAQ: CSCO) and Check Point (NASDAQ: CHKP) for their cybersecurity needs, SAM targets small and medium-sized enterprises, which make up the vast majority of companies – including 99% of all businesses in Europe. Unlike large, security-conscious multinationals, most Wi-Fi networks in small businesses and home offices are unmanaged, unsecured and without an information officer, leaving them prey to hackers. “The fast adoption of 5G, combined with the proliferation of smart devices operating on unsupervised networks, can be catastrophic for millions of home and business users. Even with the implementation of basic security requirements on IoT devices, the threat of a silent invasion through them is very real,” says Rauscher. “SAM is the best and most cost-efficient defense to this threat and we’re proud that our solution, which is constantly adopting to the changing threat landscape, is being adopted by some of the world’s top providers.” SAM’s platform is securing networks provided by some of the largest telecommunication companies in the world. including Verizon (NYSE: VZ) in the U.S., Virgin Media in the U.K., Orange in Belgium, Bezeq in Israel and other major European providers. The company’s cloud-based software can work with any system and is deployed remotely, which means the customer doesn’t have to fiddle with complicated settings or pieces of hardware. SAM’s system works automatically through the user’s router or other onsite gateway – usually provided by an internet service provider or as an off-the-shelf product. Unrecognized Devices SAM has a special relationship with Verizon, which is both a client and an investor through its investment arm Verizon Ventures. Verizon and SAM also launched the Device ID platform, allowing users to monitor their home network for new or previously unrecognized devices. This allows customers to manage certain details of their devices, like customized naming conventions, allowing for better control of their home network and connected devices. This visibility also results in improved customer service and troubleshooting from the viewpoint of Verizon, which is truly able to “see” the connected home network. SAM has several key investors including BlackBerry, which co-led the Series B round with Verizon Ventures, Intel Capital, Night Dragon, Target Global, Ericsson, ADT Security Corporation and Blumberg Capital. OurCrowd is leading SAM’s Series C investment round, which is now funding. The company is constantly updating its security in response to new threats identified on the networks. “We employ a data-driven approach to identify emerging threats and attacks on these IoT devices, relying on data from millions of IoT devices across our networks,” says Rauscher. “We’re actively looking and researching vulnerabilities in IoT devices we believe pose a significant threat to our customers.” IoT regulation Western governments are aware of the security risks posed by IoT devices. “Malicious cyber actors may leverage your home network to gain access to personal, private, and confidential information,” the U.S. NSA warned in Best Practices for Securing Your Home Network, published in 2023. Last July, the U.S. government announced a national IoT security label that manufacturers and retailers can use to assure consumers that their smart connected IoT devices meet a certain level of cyber-safety. The EU is not making IoT security optional. This year, the European Commission imposed minimum requirements for the security of smart devices. Products not meeting the standards will be banned from the EU market. The UK has similar legislation due to take effect in April 2024. While such government programs don’t apply to IoT devices that are already in use today, they will create a more informed consumer and raise awareness among other parties in the ecosystem, such as retailers or ISPs, motivating them to take action. For more information about the SAM Seamless Network investment round on the OurCrowd platform, click HERE. Featured photo courtesy of SAM Seamless Network. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Lisa Graston lisa.graston@ourcrowd.com Company Website http://www.ourcrowd.com

February 28, 2024 08:00 AM Eastern Standard Time

Image

Tonix Pharmaceuticals drug TNX-102 SL gets FDA ok for US Department of Defense funded trial

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share significant news regarding the company's latest development: the clearance of the Investigational New Drug application by the U.S. Food and Drug Administration for the Phase 2 investigator-initiated OASIS trial. This trial aims to evaluate the efficacy of TNX-102 SL in reducing the severity of acute stress reaction and the frequency of acute stress disorder and post traumatic stress disorder. Dr. Lederman explained that the trial is sponsored by The University of North Carolina Institute for Trauma Recovery and is supported by a substantial 3 million dollar grant from the U.S. Department of Defense. The primary objective of the trial is to assess the safety and efficacy of TNX-102 SL in mitigating adverse posttraumatic neuropsychiatric effects among patients who present to the emergency department following a motor vehicle collision. The trial is expected to enroll approximately 180 trauma survivors across various emergency department study sites throughout the United States. Participants will be randomly assigned to receive either TNX-102 SL 5.6 mg or a placebo for a two-week course. Notably, there is currently a lack of medication available at or near the point-of-care to effectively address the needs of patients suffering from traumatic events and support their long-term health. This development underscores Tonix Pharmaceuticals' commitment to addressing unmet medical needs in the field of trauma recovery and psychiatric disorders. With the initiation of the OASIS trial, the company aims to contribute to the advancement of treatment options for individuals experiencing acute stress reactions and related neuropsychiatric sequelae following traumatic events. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

February 28, 2024 06:56 AM Eastern Standard Time

Video

Tonix Pharmaceuticals' Fibromyalgia Trial Shows Promising Results in Webinar Presentation

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share positive Phase 3 data on Tonmya, also known as TNX-102 SL, for the management of fibromyalgia, and discussed the company's plans to file for FDA approval in the second half of 2024. Dr. Lederman highlighted that Tonmya, a centrally acting, non-opioid, non-addictive bedtime medication, showed promising results in the RESILIENT Phase 3 study. The study met its pre-specified primary endpoint by significantly reducing daily pain compared to placebo in participants with fibromyalgia. Additionally, significant improvements were observed in key secondary endpoints related to sleep quality, fatigue reduction, and overall fibromyalgia symptoms and function. Based on these positive results, Tonix Pharmaceuticals plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for Tonmya for the management of fibromyalgia. The company hosted a webinar featuring key opinion leaders in fibromyalgia, highlighting the significance of the trial results. Interested individuals can access the webinar through Tonix Pharmaceuticals' website or the accompanying press release. Led by renowned experts like Professor Leslie Arnold and Professor Dan Clau, the webinar offers valuable insights into the treatment landscape for fibromyalgia. Tonix Pharmaceuticals remains committed to advancing innovative solutions for fibromyalgia and improving patient outcomes. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

February 28, 2024 06:54 AM Eastern Standard Time

Video

ARway.ai latest deal brings cutting edge technology to hospital in Kuwait

ARway.ai

ARway.ai CEO Evan Gappelberg joined Steve Darling from Proactive to share news to announce a new partnership deal with AMANAH TEKNOLOGIA, a leading technology company and system integrator based in Kuwait City, Kuwait. Under this partnership, ARway.ai will collaborate with AMANAH TEKNOLOGIA to develop a mobile application prototype for hospitals that integrates with Electronic Medical Record (EMR) systems and serves as a digital concierge for visitors and staff. The project will involve creating a prototype mobile application that enhances the hospital experience by providing AR navigation and immersive educational experiences throughout the facility. Specifically, the application will leverage ARwayKit SDK to implement AR navigation features, enabling visitors and staff to navigate the hospital premises efficiently and seamlessly. The prototype will be tested at Dar AlShifa Hospital in Kuwait, where it will be evaluated for its effectiveness in improving the overall hospital journey for visitors and staff. By integrating with EMR systems and offering AR navigation capabilities, the digital concierge application aims to streamline operations, enhance communication, and provide a more engaging and interactive experience for users. This partnership underscores ARway.ai's commitment to leveraging augmented reality technology to transform various industries, including healthcare. By collaborating with AMANAH TEKNOLOGIA and deploying innovative solutions like the hospital digital concierge application, ARway.ai aims to revolutionize the way people interact with technology and enhance user experiences in diverse settings. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 28, 2024 05:36 AM Eastern Standard Time

Video

TRUE Addiction & Behavioral Health: Elevating Standards of Care in Murfreesboro, Tennessee

TRUE Addiction & Behavioral Health

TRUE (Transforming Roots Unto Eternity) Addiction & Behavioral Health proudly announces its grand opening in Murfreesboro, Tennessee for individuals seeking comprehensive addiction and behavioral health services. Founded by Benjamin Dobbs, the facility stems from the urgent need for elevated standards of care in substance abuse and mental health treatment across the greater Nashville area. TRUE offers a spectrum of services addressing substance abuse, mental health disorders, and gambling and process addiction. Recent statistics underline the critical need for such services. According to the National Institute on Drug Abuse (NIDA), approximately 20.4 million adults in the United States battled a substance use disorder in 2019, with only about 10.3% receiving the specialized treatment they needed. Furthermore, NIDA indicates a concerning trend of increased drug overdose deaths with 92,000 fatalities recorded in 2020. Dobbs emphasizes, “As a leading substance abuse and mental health treatment facility, we are committed to delivering the highest quality care and fostering lasting recovery. Through evidence-based best practices and client-centered care, we equip individuals with the tools for transformation. Our approach delves into core beliefs, values, and connections, ensuring comprehensive support tailored to each client’s needs and fostering results-driven progress.” Programs offered: Partial hospitalization program (PHP): Intensive and structured care for individuals, ideal for those needing support beyond outpatient therapy without 24-hour hospitalization. Intensive outpatient program (IOP): Structured therapy and support while individuals continue living at home or in a supportive environment. Sober living homes: Structured housing offering additional accountability through drug tests and curfews, often utilized alongside PHP and IOP. Treatment services used in programs include: Cognitive Behavioral Therapy (CBT): Proven effective for various disorders, including depression, anxiety, and substance use issues. Dialectical Behavioral Therapy (DBT): Focused on managing emotions and relationships, particularly beneficial for addiction and self-harm. Holistic Therapy: Addressing physical, emotional, mental, and spiritual well-being for balanced development and coping skills. 12-Step Facilitation and Relapse Prevention: Customized aftercare plans and techniques to prevent relapse and sustain recovery. Additionally, TRUE plans to enhance community engagement among the clients with the upcoming opening of a 3,500-square-foot community center this spring. The center will feature a cafe, a 50-person meeting area, a meditation and yoga room, a lounge area, and a gaming area with ping pong, a pool table, and cornhole. These amenities are designed to aid in the healing process, promoting relaxation and stress reduction in clients between therapy sessions, as well as improving their comfort and ability to concentrate during therapy. TRUE Addiction & Behavioral Health in Murfreesboro, Tennessee, is dedicated to delivering compassionate and personalized care to individuals facing addiction and mental health challenges. Unlike standardized approaches, TRUE devises tailored treatment plans, equipping clients with the tools needed for lasting recovery. It stands as the only facility in Tennessee offering outpatient care for both mental health and substance abuse. For more information about programs and scheduling tours, visit https://trueaddictionbh.org/. Contact Details R Public Relations Madison Baber +1 210-213-2426 madison@rprfirm.com Company Website https://trueaddictionbh.org/

February 27, 2024 01:31 PM Eastern Standard Time

Image

Express Gene Molecular Diagnostics Laboratory Receives Accreditation from the College of American Pathologists

ExpressGene Lab

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Express Gene Molecular Diagnostics Laboratory (Express Gene Lab), following a comprehensive on-site inspection by CAP inspectors, who are experienced professionals in pathology and laboratory medicine. This accreditation is a testament to Express Gene's adherence to the highest standards of quality and risk management, contributing significantly to enhanced patient outcomes. Express Gene Lab, was informed of this prestigious global recognition and praised for the laboratory's commitment to excellence in its services. Express Gene Lab is now among the elite group of over 8,000 CAP-accredited facilities worldwide. Express Gene Lab Team expressed their enthusiasm: "Achieving CAP accreditation is a monumental milestone for Express Gene Lab. It underscores our dedication to providing the highest quality of laboratory services and our commitment to patient care. This accreditation affirms our relentless pursuit of excellence and our unwavering commitment to the health and safety of our patients." The CAP accreditation process is rigorous, involving detailed scrutiny of the laboratory’s procedures, records, quality control measures, staff qualifications, equipment, facilities, safety protocols, and overall management. This evaluation ensures adherence to the latest best practices in laboratory medicine.. Express Gene Lab takes immense pride in this achievement, which reflects our pathology and laboratory medicine team's hard work and dedication to high-quality patient care. About the College of American Pathologists: The CAP is the world’s largest organization of board-certified pathologists and a leading provider of laboratory accreditation and proficiency testing programs. It serves patients, pathologists, and the public by promoting excellence in pathology and laboratory medicine globally. For more information, visit CAP.org and follow the stories of pathologists making a difference in patient care at yourpathologist.org. Rooted in pathologist expertise, CAP collaborates with laboratories globally to enhance the quality of laboratory medicine, aiming for operational excellence, diagnostic confidence, and superior patient care About Express Gene Molecular Diagnostics Laboratory Express Gene Lab is at the forefront of molecular diagnostics, offering a comprehensive suite of genetic testing services designed to provide insightful and actionable health information. Our state-of-the-art laboratory is equipped with advanced technology to ensure accuracy and reliability across all tests, including pharmacogenomics, cancer risk assessment, neurogenetic disorders, and prenatal screenings. At Express Gene Lab, we are committed to making genetic testing accessible and understandable, empowering individuals and healthcare providers to make informed decisions about health and treatment strategies. Our team of expert geneticists, pathologists, and laboratory technicians work diligently to uphold the highest standards of quality and confidentiality. With a patient-centric approach, we strive to deliver not just results, but also the support and resources needed to navigate genetic health. Express Gene Lab is proud to be an accredited facility by the College of American Pathologists (CAP), reflecting our dedication to excellence in laboratory services. For Press Inquires: AlphaBull (800) 530-0412 www.Pubcowire.com For more information about our services or to request a testing kit, please visit our website www.expressgene.me/collection or contact us directly. Our customer service team is available to answer any questions and assist with your genetic testing needs. At Express Gene Lab, your health is our priority, and we are dedicated to providing you with the highest level of service and care. Contact Details ExpressGene Lab Lab Direct +1 786-250-3419 info@expressgene.us Company Website https://www.expressgene.us

February 27, 2024 12:54 PM Eastern Standard Time

CSD Social Venture Fund and Gallaudet University Present "Holographic Horizons: Bridging the Educational Divide" at SXSW

Communication Service for the Deaf

CSD Social Venture Fund and Gallaudet University have partnered with Proto Inc., to utilize Proto’s “Epic” holoportation technology as a groundbreaking tool in delivering lifelike, interactive American Sign Language (ASL) education for students who are Deaf and hard of hearing. "Deaf education is on the brink of a transformative leap, where geographical, socioeconomic, and communication disparities will no longer be barriers to quality learning," said Rosa Lee Timm, Division President of CSD Social Venture Fund. “Epic allows students to see and interact with remote instructors as if they are present in the same space, making it an inclusive environment that celebrates and nurtures diversity.” The demo and event, “Holographic Horizons: Bridging the Educational Divide” is set to debut at the Southwest (SXSW) festival on March 4th, 2024, led by panelists Rosavetta Jackson, CSD Social Venture Fund Program Manager; Topher Myers, an educational technology expert; and Dr. Laurene E. Simms, a leading voice for inclusive learning. The panelists will discuss how the Epic holoportation device from Proto Inc can serve as a medium for improving educational accessibility, including how it allows for greater clarity of information exchanged in ASL due to its usage of 3D space over more traditional 2D spaces found in video conferencing platforms. Epic’s lack of physical proximity will be highlighted to show how it opens doors to unimaginable use within the realm of universal design in classroom environments, creating far more learning opportunities and accessibility for students affected by inequity and geopolitics. For more information and to register for the event, please visit: https://sxswedu.com About CSD Social Venture Fund Founded in 2017, the CSD Social Venture Fund aims to support Deaf entrepreneurs in creating jobs, breaking down barriers, and serving as positive representations within the Deaf community. By investing in Deaf-owned businesses and providing resources for entrepreneurs, they seek to strengthen the community of Deaf entrepreneurs and, in turn, the Deaf community at large. About Gallaudet University Gallaudet University has been a cornerstone of the deaf and signing community for over 150 years, promoting the intellectual and professional advancement of deaf and hard of hearing individuals through American Sign Language and English. It upholds a proud tradition of research, scholarly activity, and prepares its graduates for careers in a dynamic, technological world. Gallaudet's vision is to be the university of first choice for the most qualified deaf and hard of hearing students globally. Contact Details Communication Service for the Deaf Rosa Lee Timm +1 518-569-1841 svf@csdsvf.com Company Website https://www.csd.org/

February 27, 2024 11:15 AM Eastern Standard Time

Video

PathAI Launches New Pathologist-Centric Features on AISight to Enable Efficient Case Review through Intelligent Case Prioritization and Real-Time Multi-Institutional Collaboration

PathAI

PathAI, Inc., a leading AI-powered precision pathology company, today announced the availability of two new features on the AISight digital pathology image management system – an Intelligent Caselist and AISight Live. AISight is a cloud-based platform that serves as a central hub for case management, image management, and best-in-class artificial intelligence to enable efficient end-to-end digital pathology workflows. The latest AISight enhancements represent PathAI’s ongoing commitment to empowering pathologists with cutting-edge solutions that improve pathology assessment and laboratory operations and lay the groundwork for broader implementation of AI tools in pathology. AISight Live includes a suite of features to optimize real-time collaboration for a variety of use cases, and its Sync view allows users to follow one another as they navigate the slide – providing real-time case review and interaction with users remotely. An AISight Live Participants list allows users to invite other pathologists for ‘over the shoulder’ and multi-headed scope review/consults, live tumor boards, educational seminars and training, and anonymized viewing to mask PHI if necessary. “The AISight Live collaboration suite marks a significant leap in optimizing remote interactions amongst pathologists,” says Eric Walk, PathAI Chief Medical Officer. “This feature holds immense promise in enhancing collaborative efforts, fostering knowledge exchange, driving resident education, and ultimately improving collaboration through efficient and dynamic pathology workflows.” The Intelligent Caselist features an information-rich data table and three filterable charts, providing pathologists and lab personnel a more streamlined view of their case workload, and allowing for embedded AI to assist in case prioritization. “We’re confident that the AISight Live and the Intelligent Caselist features will simplify pathology workflows and speed up the more tedious tasks – such as case prioritization,” said Pete Romanowich, PathAI Vice President of Program Management and Platform Product. “These features will streamline and optimize pathologist workflows, providing pathologists more time to operate at the top of their license and focus their attention where it matters most.” The AISight platform was created with input from hundreds of pathologists from dozens of institutions, and its launch, and enhancements, underpins all the work PathAI does to support pathologists, biopharma partners and those in the academic research community. AISight Live and the Intelligent Caselist are another critical step in PathAI’s quest to improve patient outcomes with AI-powered pathology. PathAI launched AISight as an IMS in September 2023. Many leading anatomic pathology laboratories ranging from reference laboratories, to independent laboratories and academic medical centers are now using AISight. To learn more about AISight, PathAI’s Image Management System, join our next webinar on February 29, for a live demo of the latest AISight enhancements and an overview of our 2024 product roadmap. AISight is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

February 27, 2024 10:00 AM Eastern Standard Time

1 ... 28 29 30 31 32 ... 268